News

‘Tesla Builds First Supercharging Station In Alaska’ -InsideEVs

https://insideevs.com/news/529089/tesla-builds-first-supercharger-alaska/amp/

byMichael Horton

August 26, 2021

1 minute read

https://insideevs.com/news/529089/tesla-builds-first-supercharger-alaska/amp/

Reported Late Thursday, ANAVEX2–73 Phase 2B/3 Study Met Primary And Key Secondary Endpoints, Showing Statistically Significant Reduction Of Clinical Decline In Global Clinical Study Of Patients With Early Alzheimer’s Disease; Shares Currently Halted

By Benzinga Newsdesk

Today, 6:45 AM

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically

AVXL

Baird Initiates Coverage On Paymentus Holdings with Outperform Rating, Announces Price Target of $34

By Benzinga Newsdesk

Today, 6:45 AM

Baird analyst David Koning initiates coverage on Paymentus Holdings (NYSE:PAY) with a Outperform rating and announces Price Target of $34.

PAY

Taiwan Semiconductor is Estimated to have Revenues of $17.024B from Fulfilling Apple Orders in 2022

By Charles Gross

Today, 6:45 AM

-DigiTimes https://www.digitimes.com/news/a20220425PD202/apple-tsmc.html

AAPL

BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’

By Bill Haddad

Today, 6:45 AM

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05). NE3107 is

BIVI

‘Tesla Builds First Supercharging Station In Alaska’ -InsideEVs

Related Posts

Reported Late Thursday, ANAVEX2–73 Phase 2B/3 Study Met Primary And Key Secondary Endpoints, Showing Statistically Significant Reduction Of Clinical Decline In Global Clinical Study Of Patients With Early Alzheimer’s Disease; Shares Currently Halted

Baird Initiates Coverage On Paymentus Holdings with Outperform Rating, Announces Price Target of $34

Taiwan Semiconductor is Estimated to have Revenues of $17.024B from Fulfilling Apple Orders in 2022

BioVie Announces Topline Results From Investigator-Sponsored Exploratory Biomarker And Imaging Trial Of NE3107 For Treatment Of Alzheimer’s Disease; Says ‘Vast majority of patients saw significant improvements in the Global Rating of Change’